Oosterloo Mayke, de Greef Bianca T A, Bijlsma Emilia K, Durr Alexandra, Tabrizi Sarah J, Estevez-Fraga Carlos, de Die-Smulders Christine E M, Roos Raymund A C
Department of Neurology Maastricht University Medical Center Maastricht The Netherlands.
Department of Neurology Leiden University Medical Center Leiden The Netherlands.
Mov Disord Clin Pract. 2021 Jan 31;8(3):352-360. doi: 10.1002/mdc3.13148. eCollection 2021 Apr.
Determination of disease onset in Huntington's disease is made by clinical experience. The diagnostic confidence level is an assessment regarding the certainty about the clinical diagnosis based on motor signs. A level of 4 means the rater has ≥99% confidence motor abnormalities are unequivocal signs of disease. However, it does not state which motor abnormalities are signs of disease and how many must be present.
Our aim is to explore how accurate the diagnostic confidence level is in estimating disease onset using the Enroll-HD data set. For clinical disease onset we use a cut-off total motor score >5 of the Unified Huntington's Disease Rating Scale. This score is used in the TRACK-HD study, with ≤5 indicating no substantial motor signs in premanifests.
At baseline premanifest participants who converted to manifest (converters) and non-converters were compared for clinical symptoms and diagnostic confidence level. Clinical symptoms and diagnostic confidence levels were longitudinally displayed in converters.
Of 3731 eligible participants, 455 were converters and 3276 non-converters. Baseline diagnostic confidence levels were significantly higher in converters compared to non-converters ( < 0.001). 232 (51%) converters displayed a baseline motor score >5 (mean = 6.7). Converters had significantly more baseline clinical symptoms, and higher disease burden compared to non-converters ( < 0.001). Diagnostic confidence level before disease onset ranged between 1 and 3 in converters.
According to this data the diagnostic confidence level is not an accurate instrument to determine phenoconversion. With trials evaluating disease modifying therapies it is important to develop more reliable diagnostic criteria.
亨廷顿舞蹈症的疾病发病时间通过临床经验来确定。诊断置信水平是基于运动体征对临床诊断确定性的一种评估。4级意味着评估者有≥99%的信心认为运动异常是明确的疾病体征。然而,它并未说明哪些运动异常是疾病体征以及必须出现多少种。
我们的目的是利用Enroll-HD数据集探究诊断置信水平在估计疾病发病方面的准确性如何。对于临床疾病发病,我们采用统一亨廷顿舞蹈症评定量表总运动评分>5作为临界值。该评分用于TRACK-HD研究,≤5表明前驱期无明显运动体征。
在基线时,对转化为显性症状的前驱期参与者(转化者)和未转化者的临床症状和诊断置信水平进行比较。在转化者中纵向展示临床症状和诊断置信水平。
在3731名符合条件的参与者中,455名是转化者,3276名是未转化者。与未转化者相比,转化者的基线诊断置信水平显著更高(<0.001)。232名(51%)转化者的基线运动评分>5(平均=6.7)。与未转化者相比,转化者有更多的基线临床症状和更高的疾病负担(<0.001)。转化者在疾病发病前的诊断置信水平在1至3级之间。
根据这些数据,诊断置信水平不是确定表型转化的准确工具。在评估疾病修饰疗法的试验中,制定更可靠的诊断标准很重要。